Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

44.73 +1.35 (+3.11%)
Streaming Delayed Price Updated: 11:54 AM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
42 43 Next >
Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them
The list of Super Bowl LIX commercials and the companies behind the Super Bowl ads. 
Via Benzinga
Hims & Hers Takes Aim At Big Pharma In Controversial Super Bowl Ad — Retail Loves The Fight
The commercial aired Sunday night on Fox and positioned obesity as "America's deadliest epidemic" while criticizing the $160 billion weight-loss industry and the broader healthcare system. 
Via Stocktwits
Hims & Hers Health Unusual Options Activity
 
Via Benzinga
Hims & Hers Health Unusual Options Activity For February 03
 
Via Benzinga
Unlocking the Growth Potential of NYSE:HIMS.
A fundamental analysis of (NYSE:HIMS): Is HIMS & HERS HEALTH INC (NYSE:HIMS) suited for growth investing? 
Via Chartmill
Is Hims & Hers Health Stock a Buy?
Here's a look into one of healthcare's hottest growth stocks. 
Via The Motley Fool
US Stocks To Open On A Positive Note After A String Of Bad Mondays: Recent Dip Has 'Reached Its Low Point,' Says Technical Analyst
U.S. stock futures rose on Monday following Friday's sharp fall as investors digest tariff updates and earnings reports. 
Via Benzinga
Topics World Trade
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad
Shares rocketed on Friday, but the company might not be out of hot water yet. 
Via Investor's Business Daily
EXCLUSIVE: Is Super Bowl $7M Ad Cost Worth It? 61% Say No, 18% Say They Looked Up Companies After Last Year's NFL Championship
Benzinga readers pick whether a $7 million Super Bowl cost is worth it for companies and how likely they are to look up a company that may be new to them after the big game. 
Via Benzinga
Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight
A list of Super Bowl LIX commercials and the celebrities and athletes attached to star in the ads. 
Via Benzinga
Topics Artificial Intelligence
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also... 
Via Stocktwits
Hims & Hers Launches Health Collective and Community Member Council
From Hims & Hers
Via Business Wire
Hims & Hers to Announce Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
From Hims & Hers
Via Business Wire
Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio?
Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners... 
Via Benzinga
Hims & Hers Health Unusual Options Activity
 
Via Benzinga
Why the high growth investor may take a look at NYSE:HIMS.
Unlocking the high Growth Potential of HIMS & HERS HEALTH INC (NYSE:HIMS). 
Via Chartmill
Is Hims & Hers Stock in Trouble?
Via The Motley Fool
Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions 
Via MarketBeat
8 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Hims & Hers Health: A Stock to Trade or Own?
HIMS achieved remarkable growth in 2024 but now faces challenges in 2025, raising the question of whether it suits traders better than long-term investors. 
Via MarketBeat
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
Via The Motley Fool
Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
Here are three low-priced stocks you can buy today that are positioned in sector that make them solid choices to double in 2025 
Via MarketBeat
Evaluating NYSE:HIMS for Growth Investment Opportunities.
Is HIMS & HERS HEALTH INC (NYSE:HIMS) suited for growth investing? 
Via Chartmill
What 12 Analyst Ratings Have To Say About Hims & Hers Health
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Hims & Hers Stock Is Poised for a Major Surge in 2025
The focus is on GLP-1s, but there's more to Hims & Hers than one product. 
Via The Motley Fool
What's Going On With Hims & Hers Health Stock?
Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst expectations. 
Via Benzinga
Stock Picks 2024 Year In Review
Unlike 2023, 2024 was a very concentrated year, with just a few key large-cap stocks driving much of the index's returns. 
Via Talk Markets
Topics Stocks / Equities
Is Hims & Hers Health a Millionaire Maker?
Arguments are piling up for why the company might fail, but the business continues to deliver strong results. 
Via The Motley Fool
3 Hot Stocks That Can Double Again in 2025
Three unlikely winners of 2024 can lead the way in the year ahead. 
Via The Motley Fool
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.